Advanced

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden

Peeker, Ralph; Samsioe, Göran LU ; Kowalski, Jan; Andersson, Ann-Sofie and Bergqvist, Agneta (2010) In Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00 44(3). p.138-146
Abstract
Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6... (More)
Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p <0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
OAB-q, Antimuscarinic, health-related quality of life, overactive, bladder, tolterodine
in
Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00
volume
44
issue
3
pages
138 - 146
publisher
Taylor & Francis
external identifiers
  • wos:000277391100002
  • scopus:77954881755
ISSN
0036-5599
DOI
10.3109/00365591003709468
language
English
LU publication?
yes
id
375757f9-5560-44a4-b11b-5e9fc798caca (old id 1618129)
date added to LUP
2010-06-22 10:52:34
date last changed
2018-05-29 09:21:05
@article{375757f9-5560-44a4-b11b-5e9fc798caca,
  abstract     = {Objective. Overactive bladder (OAB) is a chronic condition that has a profound impact on health-related quality of life (HRQoL). This study measured changes in bother of OAB symptoms and self-perceived HRQoL over 6 months in patients treated with extended-release (ER) tolterodine in a naturalistic setting. Material and methods. This was a prospective, single-cohort observational study of patients diagnosed with OAB, naive to antimuscarinic treatment and prescribed tolterodine ER for the first time. Patients were asked to complete the Overactive Bladder Questionnaire (OAB-q) containing a symptom bother scale (0-100) and an HRQoL scale (0-100), which measures coping, social interaction, concern and sleep, at baseline and after 3 and 6 months. Results. In total, 235 patients (211 women and 24 men), with a mean age of 61 years (30-87), were recruited. The numbers of patients who completed the OAB-q were 220 and 169 at 3 and 6 months, respectively. The mean reductions in the symptom bother score from baseline were 19.6 and 19.3 at 3 and 6 months, respectively. Significant improvement (p &lt;0.0001) was seen in all HRQoL subscale scores. The proportion of responders who met the minimally important difference (change in the score of 10 or more units between baseline and 6 months) was 64% for the symptom bother score and 34-60% for the total HRQoL and subscale scores. Conclusions. OAB patients beginning treatment with tolterodine ER reported clinically significant improvement in OAB symptoms and self-perceived HRQoL over the 6 months of this observational study. The rate of discontinuation from treatment was 49%.},
  author       = {Peeker, Ralph and Samsioe, Göran and Kowalski, Jan and Andersson, Ann-Sofie and Bergqvist, Agneta},
  issn         = {0036-5599},
  keyword      = {OAB-q,Antimuscarinic,health-related quality of life,overactive,bladder,tolterodine},
  language     = {eng},
  number       = {3},
  pages        = {138--146},
  publisher    = {Taylor & Francis},
  series       = {Scandinavian Journal of Urology and Nephrology1967-01-01+01:002013-01-01+01:00},
  title        = {A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden},
  url          = {http://dx.doi.org/10.3109/00365591003709468},
  volume       = {44},
  year         = {2010},
}